

# Alberto Maria Martelli

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/94233/alberto-maria-martelli-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

158  
papers

12,076  
citations

52  
h-index

107  
g-index

163  
ext. papers

13,526  
ext. citations

5.6  
avg. IF

5.61  
L-index

#	Paper	IF	Citations
158	Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53.. <i>Cells</i> , <b>2022</b> , 11,	7.9	1
157	Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma.. <i>Cell Death and Disease</i> , <b>2022</b> , 13, 346	9.8	1
156	Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.. <i>Aging</i> , <b>2022</b> , 14, 3365-3386	5.6	0
155	Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies. <i>Cells</i> , <b>2022</b> , 11, 1812	7.9	1
154	Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. <i>Advances in Biological Regulation</i> , <b>2021</b> , 100840	6.2	0
153	GSK-3 Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. <i>Cells</i> , <b>2021</b> , 10,	7.9	7
152	GSK-3: a multifaceted player in acute leukemias. <i>Leukemia</i> , <b>2021</b> , 35, 1829-1842	10.7	4
151	Regulation of p53 and NF- $\kappa$ B transactivation activities by DGK $\alpha$ in catalytic activity-dependent and -independent manners. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2021</b> , 1868, 118953	4.9	1
150	Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. <i>Advances in Biological Regulation</i> , <b>2021</b> , 79, 100780	6.2	3
149	Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. <i>Cells</i> , <b>2020</b> , 9,	7.9	67
148	Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells. <i>Cells</i> , <b>2020</b> , 9,	7.9	7
147	The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias. <i>Cancers</i> , <b>2020</b> , 12,	6.6	17
146	The Role Played by Wnt/ $\beta$ Catenin Signaling Pathway in Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	18
145	Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2020</b> , 1867, 118731	4.9	31
144	Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. <i>Aging</i> , <b>2020</b> , 12, 10194-10210	5.6	11
143	Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2020</b> , 1867, 118635	4.9	15
142	Abilities of $\beta$ Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , <b>2020</b> , 75, 100672	6.2	7

141	Targeting Wnt/βcatenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , <b>2020</b> , 235, 5413-5428	7	23
140	B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
139	Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of -Rearrangements: A Novel Therapeutic Strategy for Pediatric AML. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
138	Cancer therapy and treatments during COVID-19 era. <i>Advances in Biological Regulation</i> , <b>2020</b> , 77, 100739-100752	6.2	19
137	New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia. <i>Advances in Biological Regulation</i> , <b>2019</b> , 74, 100649	6.2	1
136	The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response. <i>Cancers</i> , <b>2019</b> , 11,	6.6	17
135	Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , <b>2019</b> , 73, 100633	6.2	15
134	Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2019</b> , 1866, 1322-1337	4.9	10
133	Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. <i>Advances in Biological Regulation</i> , <b>2019</b> , 72, 22-40	6.2	7
132	Targeting mTOR in Acute Lymphoblastic Leukemia. <i>Cells</i> , <b>2019</b> , 8,	7.9	25
131	The Cutting Edge: The Role of mTOR Signaling in Laminopathies. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	17
130	Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , <b>2019</b> , 71, 172-182	6.2	25
129	Metformin influences drug sensitivity in pancreatic cancer cells. <i>Advances in Biological Regulation</i> , <b>2018</b> , 68, 13-30	6.2	34
128	Drug discovery targeting the mTOR pathway. <i>Clinical Science</i> , <b>2018</b> , 132, 543-568	6.5	46
127	Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update. <i>Journal of Cellular Physiology</i> , <b>2018</b> , 233, 6440-6454	7.4	23
126	Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells. <i>Advances in Biological Regulation</i> , <b>2018</b> , 68, 2-9	6.2	14
125	Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticals. <i>Advances in Biological Regulation</i> , <b>2018</b> , 67, 190-211	6.2	21
124	Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	24

123	Roles of p53, NF- $\kappa$ B and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. <i>Advances in Biological Regulation</i> , <b>2018</b> , 69, 43-62	6.2	16
122	Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , <b>2018</b> , 233, 1796-1811	7	22
121	Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. <i>Advances in Biological Regulation</i> , <b>2018</b> , 69, 16-34	6.2	20
120	Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases. <i>Advances in Biological Regulation</i> , <b>2017</b> , 65, 77-88	6.2	31
119	Protective effect of different antioxidant agents in UVB-irradiated keratinocytes. <i>European Journal of Histochemistry</i> , <b>2017</b> , 61, 2784	2.1	18
118	Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. <i>Aging</i> , <b>2017</b> , 9, 1477-1536	5.6	112
117	Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. <i>Oncotarget</i> , <b>2017</b> , 8, 14221-14250	3.3	68
116	Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis. <i>Advances in Biological Regulation</i> , <b>2017</b> , 63, 32-48	6.2	28
115	PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. <i>Oncotarget</i> , <b>2017</b> , 8, 23213-23227	3.3	10
114	Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. <i>Oncotarget</i> , <b>2017</b> , 8, 76525-76557	3.3	15
113	Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression. <i>Oncotarget</i> , <b>2017</b> , 8, 113013-113033	3.3	8
112	Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2016</b> , 1863, 449-463	4.9	81
111	Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation. <i>Advances in Biological Regulation</i> , <b>2016</b> , 60, 151-159	6.2	104
110	Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2016</b> , 1863, 438-448	4.9	56
109	Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. <i>Journal of Hematology and Oncology</i> , <b>2016</b> , 9, 114	22.4	33
108	The therapeutic potential of mTOR inhibitors in breast cancer. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 82, 1189-1212	3.8	72
107	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , <b>2016</b> , 12, 1-222	10.2	3838
106	Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells. <i>Advances in Biological Regulation</i> , <b>2016</b> , 60, 61-87	6.2	26

105	Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , <b>2016</b> , 7, 55690-55703	3-3	11
104	Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. <i>Oncotarget</i> , <b>2016</b> , 7, 79842-79853	3-3	17
103	Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF- $\kappa$ B. <i>Oncotarget</i> , <b>2016</b> , 7, 1323-40	3-3	30
102	Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. <i>Current Pharmaceutical Design</i> , <b>2016</b> , 22, 2358-88	3-3	30
101	Effects of mutations in Wnt/ $\beta$ -catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2016</b> , 1863, 2942-2976	4-9	101
100	Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. <i>Advances in Biological Regulation</i> , <b>2015</b> , 59, 65-81	6.2	98
99	Tyrosol prevents apoptosis in irradiated keratinocytes. <i>Journal of Dermatological Science</i> , <b>2015</b> , 80, 61-8	4.3	30
98	Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. <i>Advances in Biological Regulation</i> , <b>2015</b> , 57, 75-101	6.2	76
97	Autophagy in acute leukemias: a double-edged sword with important therapeutic implications. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2015</b> , 1853, 14-26	4-9	58
96	Modulation of TGF $\beta$ 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. <i>Oncotarget</i> , <b>2015</b> , 6, 7424-37	3-3	24
95	Current treatment strategies for inhibiting mTOR in cancer. <i>Trends in Pharmacological Sciences</i> , <b>2015</b> , 36, 124-35	13.2	195
94	Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , <b>2015</b> , 6, 6597-610	3-3	23
93	PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. <i>Oncotarget</i> , <b>2015</b> , 6, 10399-414	3-3	29
92	The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. <i>Oncotarget</i> , <b>2015</b> , 6, 17147-60	3-3	28
91	Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. <i>Oncotarget</i> , <b>2015</b> , 6, 32089-103	3-3	30
90	DGK $\alpha$ under stress conditions: to be nuclear or cytoplasmic, that is the question <i>Advances in Biological Regulation</i> , <b>2014</b> , 54, 242-53	6.2	29
89	Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy. <i>Advances in Biological Regulation</i> , <b>2014</b> , 54, 176-96	6.2	64
88	Antioxidants in the prevention of UVB-induced keratinocyte apoptosis. <i>Journal of Photochemistry and Photobiology B: Biology</i> , <b>2014</b> , 141, 1-9	6.7	24

87	Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. <i>Advances in Biological Regulation</i> , <b>2014</b> , 56, 6-21	6.2	31
86	Targeting breast cancer initiating cells: advances in breast cancer research and therapy. <i>Advances in Biological Regulation</i> , <b>2014</b> , 56, 81-107	6.2	28
85	Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review). <i>International Journal of Oncology</i> , <b>2014</b> , 45, 909-18	4.4	19
84	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. <i>Oncotarget</i> , <b>2014</b> , 5, 4603-50	3.3	179
83	GSK-3 as potential target for therapeutic intervention in cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 2881-911	3.3	332
82	Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. <i>Cell Cycle</i> , <b>2014</b> , 13, 2237-47	4.7	28
81	GSK-3 $\alpha$ a key regulator of breast cancer drug resistance. <i>Cell Cycle</i> , <b>2014</b> , 13, 697-8	4.7	7
80	MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , <b>2014</b> , 5, 120-30	3.3	21
79	Assessment of the effect of sphingosine kinase inhibitors on apoptosis, unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. <i>Oncotarget</i> , <b>2014</b> , 5, 7886-901	3.3	30
78	Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. <i>Oncotarget</i> , <b>2014</b> , 5, 10034-47	3.3	44
77	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways <b>2013</b> , 331-372		1
76	Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. <i>Expert Opinion on Therapeutic Targets</i> , <b>2013</b> , 17, 921-36	6.4	11
75	Nuclear phospholipase C $\beta$ signaling, epigenetics and treatments in MDS. <i>Advances in Biological Regulation</i> , <b>2013</b> , 53, 2-7	6.2	29
74	Cytoplasmic localization of DGK $\beta$ exerts a protective effect against p53-mediated cytotoxicity. <i>Journal of Cell Science</i> , <b>2013</b> , 126, 2785-97	5.3	28
73	Novel approaches to target cancer initiating cells-eliminating the root of the cancer. <i>Advances in Biological Regulation</i> , <b>2012</b> , 52, 249-64	6.2	13
72	PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy. <i>Advances in Biological Regulation</i> , <b>2012</b> , 52, 214-27	6.2	18
71	Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. <i>Expert Opinion on Therapeutic Targets</i> , <b>2012</b> , 16, 729-42	6.4	34
70	The emerging multiple roles of nuclear Akt. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2012</b> , 1823, 2168-78	4.9	134

69	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. <i>Oncotarget</i> , <b>2012</b> , 3, 1068-111	3-3	250
68	Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. <i>Oncotarget</i> , <b>2012</b> , 3, 954-87	3-3	214
67	Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). <i>British Journal of Haematology</i> , <b>2012</b> , 156, 205-12	4-5	55
66	DGKs degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry. <i>Cellular Signalling</i> , <b>2012</b> , 24, 1573-82	4-9	19
65	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. <i>Cell Cycle</i> , <b>2012</b> , 11, 4447-61	4-7	21
64	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. <i>Oncotarget</i> , <b>2012</b> , 3, 371-94	3-3	98
63	Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. <i>Oncotarget</i> , <b>2012</b> , 3, 811-23	3-3	53
62	Effects of ectopic expression of NGAL on doxorubicin sensitivity. <i>Oncotarget</i> , <b>2012</b> , 3, 1236-45	3-3	13
61	A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. <i>Oncotarget</i> , <b>2012</b> , 3, 1615-28	3-3	51
60	Advances in targeting signal transduction pathways. <i>Oncotarget</i> , <b>2012</b> , 3, 1505-21	3-3	39
59	Nuclear phosphoinositides: location, regulation and function. <i>Sub-Cellular Biochemistry</i> , <b>2012</b> , 59, 335-615	5	27
58	Physiology and pathology of nuclear phospholipase C $\beta$ . <i>Advances in Enzyme Regulation</i> , <b>2011</b> , 51, 2-12		16
57	Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , <b>2011</b> , 226, 822-31	7	52
56	Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. <i>Journal of Cellular Physiology</i> , <b>2011</b> , 226, 2762-81	7	124
55	Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. <i>Cell Cycle</i> , <b>2011</b> , 10, 3003-15	4-7	71
54	Nuclear phosphoinositides and their roles in cell biology and disease. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , <b>2011</b> , 46, 436-57	8-7	28
53	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. <i>Aging</i> , <b>2011</b> , 3, 192-222	5-6	437
52	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. <i>Oncotarget</i> , <b>2011</b> , 2, 135-64	3-3	456

51	Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity. <i>Oncotarget</i> , <b>2011</b> , 2, 109-12	3-3	17
50	Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. <i>Oncotarget</i> , <b>2011</b> , 2, 538-50	3-3	69
49	Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. <i>Cancer Research</i> , <b>2010</b> , 70, 8097-107	10.1	136
48	The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. <i>Cell Cycle</i> , <b>2010</b> , 9, 1781-91	4-7	97
47	The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology. <i>Cancers</i> , <b>2010</b> , 2, 1576-96	6.6	32
46	Identification of a functional nuclear export sequence in diacylglycerol kinase-zeta. <i>Cell Cycle</i> , <b>2010</b> , 9, 384-8	4-7	24
45	Inositide signaling in the nucleus: from physiology to pathology. <i>Advances in Enzyme Regulation</i> , <b>2010</b> , 50, 2-11		16
44	The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2010</b> , 1803, 991-1002	4-9	97
43	The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. <i>Histology and Histopathology</i> , <b>2010</b> , 25, 669-80	1.4	29
42	The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. <i>Oncotarget</i> , <b>2010</b> , 1, 89-103	3-3	200
41	Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 782-90	2.2	52
40	Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. <i>Cancer Research</i> , <b>2009</b> , 69, 3520-8	10.1	106
39	The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant breast cancers. <i>Cell Cycle</i> , <b>2009</b> , 8, 1421-5	4-7	8
38	TIS21/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase-zeta-dependent cell cycle arrest. <i>Cellular Signalling</i> , <b>2009</b> , 21, 801-9	4-9	24
37	PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. <i>Journal of Cellular Physiology</i> , <b>2009</b> , 221, 232-47		26
36	Nuclear inositides: PI-PLC signaling in cell growth, differentiation and pathology. <i>Advances in Enzyme Regulation</i> , <b>2009</b> , 49, 2-10		39
35	Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. <i>Expert Opinion on Investigational Drugs</i> , <b>2009</b> , 18, 1333-49	5-9	94
34	Catalytic activity of nuclear PLC-beta(1) is required for its signalling function during C2C12 differentiation. <i>Cellular Signalling</i> , <b>2008</b> , 20, 2013-21	4-9	36



33	Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. <i>Cancer Research</i> , <b>2008</b> , 68, 9394-403	10.1	76
32	PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 35474-85	5.4	39
31	Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine (A443654) in T-cell acute lymphoblastic leukemia. <i>Molecular Pharmacology</i> , <b>2008</b> , 74, 884-95	4.3	31
30	Diacylglycerol kinase zeta is associated with chromatin, but dissociates from condensed chromatin during mitotic phase in NIH3T3 cells. <i>Journal of Cellular Biochemistry</i> , <b>2008</b> , 105, 756-65	4.7	23
29	Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. <i>Advances in Enzyme Regulation</i> , <b>2007</b> , 47, 64-103		63
28	The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. <i>Cancer Research</i> , <b>2007</b> , 67, 4287-94	10.1	75
27	Nuclear diacylglycerol kinase-zeta is a negative regulator of cell cycle progression in C2C12 mouse myoblasts. <i>FASEB Journal</i> , <b>2007</b> , 21, 3297-307	0.9	40
26	Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter. <i>Endocrinology</i> , <b>2007</b> , 148, 1108-17	4.8	49
25	Intranuclear 3'-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis?. <i>Cellular Signalling</i> , <b>2006</b> , 18, 1101-7	4.9	112
24	Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells. <i>Journal of Cellular Physiology</i> , <b>2006</b> , 207, 836-44	7	42
23	Subnuclear localization and differentiation-dependent increased expression of DGK-zeta in C2C12 mouse myoblasts. <i>Journal of Cellular Physiology</i> , <b>2006</b> , 209, 370-8	7	29
22	Nuclear protein kinase C. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2006</b> , 1761, 542-51	5	60
21	Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. <i>British Journal of Haematology</i> , <b>2005</b> , 129, 677-86	4.5	66
20	Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias. <i>British Journal of Haematology</i> , <b>2005</b> , 130, 716-25	4.5	40
19	Nuclear inositol lipid metabolism: more than just second messenger generation?. <i>Journal of Cellular Biochemistry</i> , <b>2005</b> , 96, 285-92	4.7	30
18	Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. <i>Journal of Cellular Physiology</i> , <b>2005</b> , 202, 623-34	7	52
17	Novel 2'-substituted, 3'-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway. <i>British Journal of Haematology</i> , <b>2004</b> , 126, 574-82	4.5	18
16	Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry. <i>British Journal of Haematology</i> , <b>2004</b> , 126, 675-81	4.5	32

15	Nuclear inositides: facts and perspectives <b>2004</b> , 101, 47-64		66
14	Nuclear diacylglycerol kinase-theta is activated in response to nerve growth factor stimulation of PC12 cells. <i>Cellular Signalling</i> , <b>2004</b> , 16, 1263-71	4.9	17
13	Expression of phospholipase C beta family isoenzymes in C2C12 myoblasts during terminal differentiation. <i>Journal of Cellular Physiology</i> , <b>2004</b> , 200, 291-6	7	39
12	Up-regulation of nuclear PLCbeta1 in myogenic differentiation. <i>Journal of Cellular Physiology</i> , <b>2003</b> , 195, 446-52	7	55
11	Threonine 308 phosphorylated form of Akt translocates to the nucleus of PC12 cells under nerve growth factor stimulation and associates with the nuclear matrix protein nucleolin. <i>Journal of Cellular Physiology</i> , <b>2003</b> , 196, 79-88	7	55
10	Diacylglycerol kinase-theta is localized in the speckle domains of the nucleus. <i>Experimental Cell Research</i> , <b>2003</b> , 287, 143-54	4.2	78
9	The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells. <i>Molecular Cancer Research</i> , <b>2003</b> , 1, 234-46	6.6	52
8	Erythropoietin-induced erythroid differentiation of K562 cells is accompanied by the nuclear translocation of phosphatidylinositol 3-kinase and intranuclear generation of phosphatidylinositol (3,4,5) trisphosphate. <i>Cellular Signalling</i> , <b>2002</b> , 14, 21-9	4.9	19
7	Molecular characterization of the human PLC beta1 gene. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2002</b> , 1584, 46-54	5	18
6	Increase in nuclear phosphatidylinositol 3-kinase activity and phosphatidylinositol (3,4,5) trisphosphate synthesis precede PKC- $\zeta$ translocation to the nucleus of NGF-treated PC12 cells. <i>FASEB Journal</i> , <b>1999</b> , 13, 2299-2310	0.9	96
5	Nuclear diacylglycerol produced by phosphoinositide-specific phospholipase C is responsible for nuclear translocation of protein kinase C-alpha. <i>Journal of Biological Chemistry</i> , <b>1998</b> , 273, 29738-44	5.4	79
4	Selective nuclear translocation of protein kinase C alpha in Swiss 3T3 cells treated with IGF-I, PDGF and EGF. <i>FEBS Letters</i> , <b>1994</b> , 347, 63-8	3.8	48
3	Nuclear localization and signalling activity of phosphoinositidase C beta in Swiss 3T3 cells. <i>Nature</i> , <b>1992</b> , 358, 242-5	50.4	300
2	Changes in nuclear inositol phospholipids induced in intact cells by insulin-like growth factor I. <i>Biochemical and Biophysical Research Communications</i> , <b>1989</b> , 159, 720-5	3.4	96
1	Rapid changes in phospholipid metabolism in the nuclei of Swiss 3T3 cells induced by treatment of the cells with insulin-like growth factor I. <i>Biochemical and Biophysical Research Communications</i> , <b>1988</b> , 154, 1266-72	3.4	90